chrysalis_top_new
chrysalis_top_new
Slide 2
Slide 2
Slide 3
Slide 3
Slide 4
Slide 4

The Chrysalin® Solution for Regenerative Medicine

Chrysalis BioTherapeutics is developing a “next generation” therapeutic approach that harnesses the body’s natural regenerative signals to protect and activate endogenous progenitor stem cells to stimulate repair and restore function to damaged tissues and organ systems.

Natural regenerative signals have evolved to initiate tissue revascularization and repair following injury. This process involves the activation of progenitor stem cells located within specific tissues such as the walls of blood vessels or in bone marrow reservoirs where activation stimulates their proliferation and migration to sites of injury.

Under normal circumstances, natural activation of progenitor cells is sufficient for tissue repair. However, aging, vascular disease, chronic infection, ischemia, and radiation all interfere with normal regenerative signaling. To overcome defective repair, many companies are developing stem cell therapies which introduce new progenitor cell populations into tissues. However, this process requires that stem or progenitor cells are isolated, or established in culture, and then injected back into the patient. This process can be bypassed by using a drug that is capable of restoring the “natural” regenerative signals to activate progenitor cells located within tissues.

Chrysalis BioTherapeutics is developing Chrysalin® brand natural thrombin peptide drugs that initiate the “natural signals” that turn on progenitor cells within bone marrow or specific tissues to replace damaged cells and initiate repair and regeneration. Our lead product, TP508, has demonstrated safety and potential efficacy in human clinical trials for dermal and orthopedic tissue repair and demonstrated efficacy in mitigating effects of myocardial ischemia and radiation exposure in preclinical studies. TP508, therefore, has the potential to change the future of regenerative medicine, save lives, and improve life’s quality for millions of people.

Clinical Target Indications

  • Wound healing/tissue repair
  • Myocardial and Peripheral Artery Disease
  • Neurodegenerative diseases
  • Stroke
  • Traumatic brain injury
Chrysalis BioTherapeutics, Inc., is committed to helping improve people's lives through innovation.
Skip to toolbar